Edition:
United Kingdom

Merrimack Pharmaceuticals Inc (MACK.OQ)

MACK.OQ on NASDAQ Stock Exchange Global Market

8.49USD
20 Apr 2018
Change (% chg)

$0.03 (+0.35%)
Prev Close
$8.46
Open
$8.43
Day's High
$8.60
Day's Low
$8.21
Volume
20,531
Avg. Vol
45,651
52-wk High
$39.85
52-wk Low
$7.41

Chart for

About

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic... (more)

Overall

Beta: 1.75
Market Cap(Mil.): $187.24
Shares Outstanding(Mil.): 13.28
Dividend: 10.55
Yield (%): --

Financials

  MACK.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -9.21 -- --
ROI: -113.12 1.58 14.38
ROE: -- 2.41 16.07

BRIEF-Merrimack Provides Business Update And Reports 2017 Financial Results

* MERRIMACK PROVIDES BUSINESS UPDATE AND REPORTS 2017 FINANCIAL RESULTS

12 Mar 2018

BRIEF-Merrimack Strengthens SHERLOC Study Of MM-121 In Non-Small Cell Lung Cancer

* MERRIMACK STRENGTHENS SHERLOC STUDY OF MM-121 IN NON-SMALL CELL LUNG CANCER

12 Mar 2018

BRIEF-Merrimack Says Dosed First Patient In Randomized Phase 2 Clinical Study Of MM-121

* MERRIMACK - ‍ DOSED FIRST PATIENT IN RANDOMIZED PHASE 2 CLINICAL STUDY OF MM-121 IN PATIENTS WITH POST-MENOPAUSAL METASTATIC BREAST CANCER​

26 Feb 2018

BRIEF-Merrimack Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln

* MERRIMACK PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING Source text :[http://bit.ly/2yGsbJv] Further company coverage:

15 Dec 2017

BRIEF-Merrimack reports Q3 loss per share from continuing operations $0.40

* Merrimack Pharmaceuticals Inc - Qtrly loss per share from continuing operations $0.40

08 Nov 2017

BRIEF-Merrimack receives orphan drug designation for MM-121 for the treatment of type of lung cancer

* Merrimack receives orphan drug designation for MM-121 for the treatment of heregulin positive non-small cell lung cancer

30 Oct 2017

Competitors

Earnings vs. Estimates